『What Comes After Ozempic? Next-Gen Weight Loss Drugs』のカバーアート

What Comes After Ozempic? Next-Gen Weight Loss Drugs

What Comes After Ozempic? Next-Gen Weight Loss Drugs

著者： Inception Point Ai
無料で聴く

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

 Dr. Ben Synth explores the cutting-edge obesity drugs racing to surpass Ozempic, from Eli Lilly's triple-receptor retatrutide to Novo Nordisk's amylin strategies and the quest for a daily pill. Discover how these next-generation therapies promise weight loss exceeding 24% and could transform treatment forever.

For more content like this, visit QuietPlease.ai

This show includes AI-generated content.Copyright 2025 Inception Point Ai 科学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • What Comes After Ozempic? Next-Gen Weight Loss Drugs - Discover the future of medicine with Dr. Ben Synth

    What Comes After Ozempic? Next-Gen Weight Loss Drugs - Discover the future of medicine with Dr. Ben Synth
    2026/04/07
    Join Dr. Ben Synth as he explores next-generation weight loss medications making Ozempic look like just the beginning. From triple-receptor drugs shattering clinical trial records to amylin becoming pharmaceutical gold, discover breakthrough treatments racing toward FDA approval—including the holy grail daily pill replacing injections forever.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    続きを読む 一部表示
    1 分
  • What Comes After Ozempic? - The Pill Race: Can an Oral Drug Kill the Needle?

    What Comes After Ozempic? - The Pill Race: Can an Oral Drug Kill the Needle?
    2026/04/07
    Ben Synth explores whether pharmaceutical companies can create an oral obesity pill as effective as current injectable GLP-1 drugs. He examines promising candidates like Structure Therapeutics' aleniglipron and Novo Nordisk's oral amycretin, explaining why delivering peptides through pills is so chemically challenging and what breakthrough could mean for global access.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    続きを読む 一部表示
    26 分
  • What Comes After Ozempic? - The Amylin Gambit: Novo's Bet on a Forgotten Hormone

    What Comes After Ozempic? - The Amylin Gambit: Novo's Bet on a Forgotten Hormone
    2026/04/07
    Ben Synth explores how Novo Nordisk is betting on amylin, a long-overlooked hormone, to create the next generation of obesity drugs. From CagriSema's 20% weight loss to amycretin's stunning 24% in just 36 weeks, these dual-action therapies could dethrone semaglutide by targeting appetite through complementary brain pathways—rewriting the obesity treatment playbook.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    続きを読む 一部表示
    28 分
まだレビューはありません